8-K current report · filed Nov 4, 2026

Dianthus Therapeutics, Inc. /DE/ (DNTH) 8-K Current Report: November 4, 2026

Item 2.02Item EX-99.1DNTH overview

Short answer

Dianthus Therapeutics, Inc. /DE/ (DNTH) filed an 8-K current report with the SEC on November 4, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Press release covers Dianthus Therapeutics’ quarter ended September 30, 2026 financial results.

Dianthus Therapeutics, Inc. /DE/ 8-K event analysis

AI summary of each reported item and its exhibits

Item 2.02 · Results of Operations and Financial Condition

  • Press release covers Dianthus Therapeutics’ quarter ended September 30, 2026 financial results
  • Exhibit 99.1 contains the detailed earnings figures and management commentary
  • Results announcement provides the latest update on operating performance and financial position

Item EX-99.1 · Exhibit EX-99.1

  • Q3 net loss $46.6M, or $0.81 per share, versus $36.8M, or $0.97, year over year
  • Cash, equivalents and investments $1.2B at September 30, 2026, supporting projected runway into 2030
  • CAPTIVATE interim responder rate 75% among first 40 CIDP participants, exceeding the 50% target
  • Claseprubart catalysts: MMN Phase 2 results December 2026, CIDP Part A by year-end 2027, gMG Phase 3 in 2H 2028
  • R&D expense $45.6M, up from $32.5M, reflecting expanded Phase 2 and Phase 3 development spending

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Dianthus Therapeutics, Inc. /DE/ 8-K filings

Get the next DNTH 8-K as it lands

Follow DNTH for push alerts, or ask the research agent what this filing means.